Equities

Esperion Therapeutics Inc

Esperion Therapeutics Inc

Actions
  • Price (EUR)1.54
  • Today's Change-0.013 / -0.87%
  • Shares traded0.00
  • 1 Year change+26.56%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments82167259
Total Receivables, Net483423
Total Inventory663534
Prepaid expenses4.701112
Other current assets, total------
Total current assets201247329
Property, plant & equipment, net4.681.202.56
Goodwill, net------
Intangibles, net0.060.060.06
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets206248382
LIABILITIES
Accounts payable322318
Accrued expenses644139
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total602817
Total current liabilities1569273
Total long term debt262260258
Total debt262260258
Deferred income tax------
Minority interest------
Other liabilities, total243220247
Total liabilities661572579
SHAREHOLDERS EQUITY
Common stock0.120.080.06
Additional paid-in capital1,1491,071964
Retained earnings (accumulated deficit)(1549)(1340)(1106)
Treasury stock - common(55)(55)(55)
Unrealized gain (loss)------
Other equity, total00.00(0.03)
Total equity(455)(324)(197)
Total liabilities & shareholders' equity206248382
Total common shares outstanding1187561
Treasury shares - common primary issue1.991.991.99
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.